A Possible Role for Pioglitazone in the Management of Depressive Symptoms in Metabolic Syndrome Patients (EPICAMP Study): A Double Blind, Randomized Clinical Trial

Table 2

The pair-wise and trend analyses of changes in assessed variables in pioglitazone and placebo groups in repeated measurements.

Variable (mean ± SD)		Placebo	Pioglitazone	value
Depression score	Baseline	6.29 ± 4.23	5.26 ± 3.47	.177
	Week 12	5.59 ± 4.47	4.81 ± 3.75	.339
	Week 24	4.84 ± 3.96	3.04 ± 3.02	.011
	value	0.006	<.001
Anxiety score	Baseline	7.25 ± 4.55	6.23 ± 4.07	.227
	Week 12	4.86 ± 4.79	4.43 ± 4.87	.652
	Week 24	3.75 ± 3.30	2.91 ± 2.85	.168
	value	<.001	<.001
Stress score	Baseline	2.76 ± 2.87	1.87 ± 2.48	.091
	Week 12	1.82 ± 2.57	1.55 ± 2.18	.555
	Week 24	1.45 ± 2.29	1.13 ± 1.70	.421
	value	.002	.098